Clinical Trial Update: Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and tolerability of Calcipotriene foam 0.005% in pediatric patients with mild-to-moderate plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Calcipotriene foam 0.005% (calcipotriene)

Snippet

Sponsor: Mayne Pharma International Pty Ltd | Conditions: Psoriasis | Phase 1 | Status: COMPLETED